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ABSTRACT This paper discusses the selection of mini-antibody (nanoantibody, nanobody® or single domain antibody) 
sequences of desired specificity by phage display-based method using a generated library of antigen-binding domains 
of special heavy-chain only antibodies (single-stranded antibodies) of immunized camel. A comprehensive comparison 
of the efficiency of parallel selection procedures was performed by using the traditional (M13KO7) and modified (with 
N-terminal deletion in the surface gIII protein) helper phages. These two methods are partly complementary, and 
by using them in parallel one can significantly improve the selection efficiency. Parallel restriction analysis (finger-
printing) of PCR-amplified cloned sequences coding for mini-antibodies (HMR-analysis) is proposed for identifying 
individual clones, as a replacement to sequencing (to a certain extent). Using this method, unique data were collected 
on the selection of mini-antibody variants with the required specificity at various stages of a multi-stage selection 
procedure. It has been shown that different sequences coding for mini-antibodies are selected in different ways, and 
that, if this feature is not taken into account, some mini-antibody variants may be lost.
KEYWORDS immunisation, phage display, helper phage, recombinant mini-antibody, fingerprinting.
ABBREVIATIONS ELISA—enzyme-linked immunosorbent assay, BSA—bovine serum albumin, hp—helper phage, 
PCR— polymerase chain reaction, HA-tag – antigenic determinant, a fragment of 9 amino acids (YPYDVPDYA) from 
the hemagglutinin protein of the influenza virus, this epitope can be efficiently detected by commercially available 
antibodies, HMR-analysis—a method proposed in this paper of parallel restriction analysis (using three restriction en-
zymes - HinfI, MspIand, and RsaI) of PCR-amplified cloned mini-antibody sequences, TNF (TNF-α)—tumour necrosis 
factor, a multifunctional anti-inflammatory cytokine, PBS—phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 2 mM KH2PO4, pH 7.4).
INTRODUCTION
This work was performed in the framework of projects 
aimed at developing new methods for passive immu-
nisation for preventive care and immunotherapy of 
infectious diseases, particularly rabies and anthrax, 
in humans and animals. In this paper, we put special 
emphasis on an analysis of sequences encoding specific 
mini-antibodies at various stages of selection that is 
based on the phage display technology [1–3].
Starting from the establishing in 2003 of collabo- in 2003 of collabo- of collabo- collabo-
ration work with Prof. S. Muyldermans’ laboratory 
at Vrije Universiteit Brussel, Belgium, we have been 
developing and using a novel technology for generat-
ing specific camel single domain mini-antibodies (also 
called nanoantibodies or nanobodies®) in the Institute 
of Gene Biology, Moscow, Russia.
Nanoantibodies are antigen recognition molecules 
that are fragments (variable domains) of unusual an- unusual an-
tibodies found in nature, along with classic antibodies, 
only in Camelidae family animals and in some carti-
laginous fishes such as sharks and ratfish [4, 5]. These 
“camel-specific” antibodies consist of dimers of a single, 
short (without the first СН1 domain) immunoglobulin 
heavy chain and are fully functional in the absence of 
the immunoglobulin light chain. Only a single variable 
domain of this antibody is necessary and sufficient in 
order to specifically recognize an antigen and bind to it. 
In contrast to the majority of recombinant antibodies, 
generated single-stranded antibodies usually demon-
strate a rather high affinity to a given antigen, because 
the first stage of their formation takes place in the ani-
mal’s organism (Camelidae), via affinity maturation in 
vivo. Nanoantibodies have several advantages over tra-
ditional antibodies and may have great prospective use 
in the future in research and in new biotechnological 
devices, as well as in clinical diagnostics and treatment. 
The advantages of nanoantibodies include their smaller 
size, new structural features (better penetration into 
tissues and the ability to recognize epitopes hidden, in-  and the ability to recognize epitopes hidden, in- epitopes hidden, in-
accessible to conventional antibodies), the possibility 
to be economically and efficiently mass-produced (in 
bacteria and yeast), good solubility, resistance to sig-
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nificant changes in temperature and рН, and simplicity 
when used for various genetic engineering operations 
[5, 6]. It is important to note that these camel-variable 
domains do not cause an evident immune response in 
primates, and their structure is closely homologous to 
the variable domains of one subclass of human IgG im-
munoglobulins (IgG3). It has been shown that these 
camel mini-antibodies can be “humanized” without 
significant loss of their specific activity, via few point 
amino acid substitutions [7]. This indicates a potential 
for the broad use of mini-antibodies as a passive im-
munisation treatment to prevent various dangerous 
infections [5, 7–9].
In our method, the first critical stage of nanoanti-
body production is inducing specific antibodies in the 
camel’s (or llama) organism by immunisation, and the 
second critical stage is selecting the clones of the nu-
cleotide sequences of the required nanoantibodies by 
phage display from the generated library of the entire 
repertoire of variable domains of special antibodies of 
the immunised animal. The latter stage is quite nontriv-
ial and has not been studied extensively. In this work, 
we have carefully studied the selection of the required 
sequences and compared the techniques using two dif-
ferent helper phages. Recently, we proposed a modified 
helper phage for a more efficient selection of the anti-
gen recognition domains of the special single-stranded 
camel antibodies (nanoantibodies) by phage display 
based on the filamentous phage М13 [10]. The use of 
a mutant M13KO7 phage called hp∆MBpIII (with N-
terminal deletion in the M13 phage gIII protein, which 
makes the phage unable to infect the bacterial cells but 
does not stop the formation of the phage particle) as a 
helper phage can in some cases significantly increase 
the selection efficiency. This has been demonstrated 
on a model system in the final (third) selection stage 
of nanoantibodies binding to the tumour necrosis fac-
tor, TNF-α. The nanoantibodies were selected from a 
library that had been specifically pre-enriched in two 
traditional selection procedures. In this work, we per-
formed a comprehensive comparison of the selection 
efficiency using both the traditional and mutant helper 
phages.
EXPERIMENTAL
Antigens and camel immunisation
A preparation of the Rabies virus and a recombinant 
protein corresponding to the Bacillus antracis lethal   
factor synthesized in a bacterial expression system 
were used as antigens for camel immunisation. The 
anthrax lethal factor was kindly provided by Dr. A. 
Kolesnikov, Laboratory of Biocatalysis, Institute of 
Bioorganic Chemistry, RAS. A rabies vaccine based 
on an inactivated attenuated RB 71/10 strain of Ra-
bies virus, produced at the Pokrov bioplant (Vladimir 
region), was kindly provided by Prof. B. S. Naroditsky 
(N.F.Gamaleya Research Institute of Epidemiology and 
Microbiology). This vaccine was used to make the Ra-
bies virus preparation. Virus particles were separated 
from the culture medium proteins by ultrafiltration 
through a membrane that is permeable to particles 
smaller than 300 kDa (Vivaspin 20 ml Concentrator, 
VS 2051, Vivascience, USA) but not to much larger 
virus particles. In parallel, the virus preparation was 
concentrated (approximately to 107 virus particles in 10 
ml of standard PBS solution). The obtained preparation 
was divided into six equal parts and frozen at –70°C for 
storage (five parts were used for five successive im-
munisation injections, and the sixth part was used for 
the selection and analysis of mini-antibodies). Before 
each immunisation stage, one of the aliquots stored at 
–70°C was thawed, then combined with 650 µg of the 
Bacillus anthracis lethal factor and mixed with an equal 
amount of Freund adjuvant. Thus, a five-stage immu- Freund adjuvant. Thus, a five-stage immu- . Thus, a five-stage immu-
nisation of a 6-year-old female Camelus bactrianus was 
performed by using the two antigen preparations de-
scribed above, mixed with equal amounts of Freund 
adjuvant (complete—only for the first injection, and 
the other 4 times—with incomplete). The second injec-
tion was made 4 weeks after the first, while the other 
three injections were made in 10-day intervals, one af-
ter another. Blood samples were taken 5 days after the 
last injection.
Construction of a nucleotide sequence library of na-
noantibodies
DNA cloning of the entire set of variable domains of 
specific single-stranded antibodies from the B-lym-
phocytes of immunised camel peripheral blood was 
performed in accordance with the standard  procedure 
(RNA isolation, cDNA synthesis, two-stage PCR with 
specific primers, insert restriction and purification, and 
insertion into phagemid vector [11–14]). This procedure 
resulted in a new specific nucleotide sequence library 
of mini-antibodies in the pHEN4 phagemid vector [11]. 
This library consisted of two sub-libraries, which were 
different in the restriction sites used for insertion into 
the phagemid vector of sequences coding for antigen 
recognition domains, (i) NcoI + NotI and (ii) PstI + NotI. 
Escherichia coli cells (strain TG1) were transformed by 
electroporation with recombinant plasmid DNA ob-
tained by ligation of the two insert sub-libraries and 
two corresponding vector sequences. Standard cloning, 
bacterial and bacteriophage M13 procedures were per-
formed following the techniques described in ref. [15, 
16]. The “Basic library of immunised camel nanoanti-
bodies” satisfied the criteria of 107 clones and about 80% RESEARCH ARTICLES
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of inserts of the expected size. Nanoantibodies with the 
required specificity were selected from the library.
Selection of nanoantibodies by phage display
The selection of camel mini-antibodies (nanoantibodies) 
by phage display, production of nanoantibodies in the 
bacterial periplasm, and the analysis of the nanoanti-
bodies’ ability to recognize a given antigen were per-
formed using the described techniques [11–14], with 
the following modifications. For selection and ELISA, 
MICROLON 600 (Greiner Bio-One) high binding poly-
styrene microtiter plates were used. Five percent Skim 
milk (Bio-Rad) and 1% BSA (Sigma-Aldrich) in PBS 
were used as blocking agents. The working concentra-
tions of ampicillin and kanamycin were 100 µ g/ml and 
70 µ g/ml, respectively.
E.  coli  K12  /  TG1  { supE  thi-1  (lac-proAB) 
(mcrB-hsdSM)5(rK- mK-) [F’ traD36 proAB lacIqZ 
M15]} (Stratagene) and E. coli K12 / WK6 {∆(lac-pro), 
galE, strA, nal; F’ lacIq Z∆M15, pro+} strains were used 
[17], as well as M13KO7 bacteriophage (New England 
Biolabs) [18] and pHEN4 phagemid [11]. The  E. coli 
strains and phagemid were provided by Prof. S. Muyl-
dermans (Vrije Universiteit Brussel, Belgium). We 
had previously prepared hp∆MBpIII modified bacte-
riophage [10] by deleting a region between the MspAI 
(1634) and BamHI (2221) sites from the М13КО7 ge-
nomic DNA. The helper phage corresponding to the 
mutant bacteriophage was produced by a two-stage 
sequential transformation of E. coli cells (strain TG1). 
At the first stage, the cells were transformed with 
pHEN4∆f1ori mutant DNA with a deleted fragment 
coding for replication initiation of the f1 filamentous 
phage (between the EcoRI (1650) and Alw44I (2345) 
sites). This deletion preserves the plasmid’s ability to 
replicate as a two-stranded DNA (by still having the 
corresponding section for replication initiation), but it 
is no longer capable of either phagemid single-stranded 
replication nor of packing to a phage particle. At the 
second stage, the cells containing pHEN4∆f1ori, and 
therefore resistant to ampicillin, were transformed with 
mutant genomic DNA (hp∆MBpIII) of the М13КО7 
bacteriophage (replicative two-stranded form) con-
taining the kanamycin resistance gene. Then, the cells 
were cultured with both antibiotics. One of the cell col-
onies was used to produce the modified helper phage. 
The phage was grown overnight in 2xTY medium 
containing kanamycin and 1 mM of isopropyl-β-D-1-
thiogalactopyranoside (used for activating the synthe-
sis of the wild-type gIII protein, coded for by pHEN4). 
Then, the phage was purified via the traditional PEG 
precipitation technique [15, 16]. The resulting phage is 
effective in infecting bacterial cells; however, its ge-
nomic DNA only codes for the gIII mutant protein. As 
a result, the daughter phages cannot infect bacteria in 
the absence of an additional plasmid coding for either 
the wild-type gIII or gIII with a mini-antibody inserted 
sequence.
Nanoantibodies binding to the Rabies virus prepa-
ration or antrax lethal factor were selected from the 
same library using two different methods in parallel. 
The first method was traditional phage display with 
the M13K07 helper phage in three selection/amplifi-
cation cycles. The blocking agents used for the cycles 
were 5% Skim milk (Bio-Rad Laboratories, USA) in 
PBS in the first cycle, 1% BSA (Amresco, USA) in PBS 
in the second cycle, and the 5% milk again in the third 
cycle. On average, ~1011 phage particles from the orig-
inal library were introduced into a well with an im-
mobilized antigen; after incubation and washing, ~106 
phage particles were eluted and remained active after 
the first selection stage, while 10 times more (~107 out 
of ~1011) amplified phage particles remained active af-
ter the second selection stage. As a result of the third 
stage, ~108 out of loaded ~1011 phage particles were 
selected, which is, similarly, about 10 times more than 
after the previous stage. This is usually an indication 
that the selection proceeds well and that specifically 
binding phage particles proliferate, with mini-anti-
bodies getting exposed on the particle’s surface, pre-
sumably ensuring its specific binding properties. After 
the last elution and neutralisation, the phage particle 
solutions at various dilution levels were used to infect 
E. coli cells (WK6 strain), then separate colonies were 
prepared on a Petri dish for the final analysis.
In parallel to the traditional procedure, nanoanti-  the traditional procedure, nanoanti-
bodies able to bind to the Rabies virus preparation 
or anthrax lethal factor were selected from the same 
library, using the mutant hp∆MBpIII helper phage 
with N-terminal deletion on the surface gIII protein 
[10]. The selection procedure was analogous to that 
described for the traditional helper phage. We should 
note that, in this case, the number of colonies grown 
after each selection stage (which corresponds to the 
number of active phage particles with nanoantibod-
ies) was significantly smaller than in the case when 
the traditional helper phage was used (100 times less 
after the first stage and 10 times less after the sec -
ond stage). Helper phage was less reliable for subse- reliable for subse-
quent infection of bacteria and amplification of eluted 
phage particles, which sometimes resulted in the loss 
of selected clones. Infecting the WK6 strain cells with 
the modified phage after elution is apparently inef-
fective (and almost impossible); therefore, in the case 
of the modified helper phage, E. coli cells of the TG1 
strain were only used for infection with eluted phage 
particles, after all selection stages, including the final 
one.88 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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A periplasmic extract containing a mini-antibody 
with a C-terminal НА tag was used to estimate the 
specificity and efficiency of the nanoantibody binding 
to the preparation of the antigen immobilised in the im-
munological plate with traditional ELISA [13, 14]. An-
ti-HA-monoclonal antibodies (CHGT-45P-Z, ICL, Inc., 
USA) conjugated with horseradish peroxidase were 
used as secondary antibodies to the НА-tag. Horserad-
ish peroxidase activity was determined by using ABTS 
(2,2’-azino-bis(3-ethylbenzothiasoline-6-sulphonate) 
as a chromogenic substrate. The absorbance was meas-
ured with a plate fluorimeter at 405 nm. There was no 
antigen in the control wells, but they were also blocked 
and  processed in parallel with the experimental wells 
containing the antigen. The number of “+” signs in the 
“ELISA signal” column in Tables 1 and 2 corresponds to 
the relative ELISA absorbance value (reflects the sum- absorbance value (reflects the sum-  (reflects the sum-
marized efficiency of expression/availability and bind-
ing of the nanoantibody from the periplasmic extract to 
the antigen immobilised in the well).
RESULTS AND DISCUSSION
HMR analysis of nanoantibody cloned nucleotide se-
quences
For interim analysis of the mini-antibody clone sam-
ples, PCR-amplification (on a given colony directly, col-
ony PCR) is usually performed. A nucleotide sequence 
coding for the mini-antibody with small adjacent sec-
tions of the pHEN4 vector phagemid is to be ampli-
fied. The PCR product is then subjected to restriction 
endonuclease (restrictase) treatment, usually HinfI. 
In the sequences coding for the nanoantibodies, there 
are both relatively conservative regions, which contain 
conservative HinfI recognition sites, and rather long 
hypervariable regions (the third region, CDR3, is the 
longest one). In the hypervariable regions, the number 
and location of the sites recognized by restrictases vary 
remarkably, hence the strong variation in the number 
and size of the split DNA fragments. We have found 
that in order to identify a given clone (a mini-antibody 
sequence variant), parallel digestion of the PCR prod-
uct with three different restrictases (HinfI, MspI, RsaI) 
yields the most reliable results.
A forward primer, RP (5’-cacacaggaaacagctatgac-3’), 
and a reverse primer, GIII (5’-ccacagacagccctcatag-3’), 
were used for PCR amplification of the cloned sequence 
coding for the nanoantibody with small adjacent seg-
ments of the pHEN4 phagemid. PCR was carried out 
in a volume of 20 µl, then the mixture was distributed 
into three tubes (6 µl of mixture into each tube), where 
parallel treatment of the PCR product was done (in 
15 µl total volume)  with three different restrictases, 
one in each tube: HinfI (Fermentas, Lithuania), MspI 
(Fermentas, Lithuania), and RsaI (SibEnzyme, Rus-
sia). The three hydrolysates were loaded into adjacent 
2.5–3% agarose gel wells for electrophoresis. The “low 
range” mixture (Fermentas) was used as a DNA frag-
ment marker. The resulting electrophoretogram (three 
gel lanes with DNA treated with the HinfI, MspI, and 
RsaI restrictases, respectively, and the fourth lane with 
marker DNA) is a reliable fingerprint image of a given 
mini-antibody coding sequence cloned in the pHEN4 
phagemid. We called this extended fingerprint analy-
sis technique, which can identify a variant of a cloned 
mini-antibody sequence, “HMR analysis.” We used the 
HMR analysis to study the selection results (samples of 
mini-antibody clones).
Figure 1 shows the HMR analysis data of some (pre-
sumably the most common) clones of the initial mini-
antibody library obtained as a result of immunisation 
and subsequent cloning. We selected and analysed all 94 
clones grown after 10-5 dilution of the base library con-
sisting of two sub-libraries. We found 85 fingerprints, 
with only 9 of them repeating twice in this sample, 
which meant that the library was very heterogeneous 
without dominating sequences. The majority of the fin-
gerprints (61) corresponded to the clones in which the 
sequences coding for the nanoantibody were inserted 
into the PstI–NotI vector restriction sites. The minority 
of the fingerprints (33) denoted with the letter “N” cor-
responded to the clones in which the sequences coding 
for the nanoantibody were inserted into the NcoI–NotI 
vector restriction sites. Very similar fingerprints found 
in both sub-libraries are underlined. Figure 1 confirms 
that the parallel use of three restrictases instead of one 
reveals the differences in many more clones. Thus, if 
we had used only HinfI, we would not have been able 
to distinguish the following clone groups: 1) 3, 38, 52, 
53, and 66 and 2) 55, 56N, 60N, 62N, 74, and 75N. Analo-
gously, much fewer clones could have been differenti-
ated using only one of the other two restrictases: MspI 
or RsaI.
This result indicates a rather wide diversity of clones 
in the original library and the high-resolution capabil-
ity of the HMR analysis. We should note that when only 
one restrictase is used (out of the three: HinfI, MspI, 
and RsaI), the number of different fingerprints is much 
smaller and, hence, the analysis less reliable; therefore, 
we decided that it was essential to use the full version 
of the HMR analysis at all further stages of the mini-
antibody clone analysis.
We used the following algorithm for nanoantibody 
sampling. With the HMR analysis, we studied a series 
of the most represented clones (those that formed no 
fewer than 24 colonies at the highest dilution of the 
library or of the eluted phage particles). All clones 
with unique fingerprints were used to produce the RESEARCH ARTICLES
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Fig. 1. HMR analy-
sis data (HMR 
fingerprints) of 
clones from the 
original library 
of cloned mini-
antibody nucle-
otide sequences. 
Ninety-four clones 
were selected and 
analysed. Eighty-
five different 
fingerprints were 
identified with only 
9 of them twice 
as repeats  in this 
set (marked as 
2x). The majority 
of fingerprints cor-
respond to clones 
with PstI-NotI in-
sertions of adapt-
ed nanoantibody 
sequences. The 
smaller part of fin-
gerprints (marked 
by the letter N) 
corresponds to 
clones with NcoI-
NotI insertions of 
adapted nanoan-
tibody sequences 
into the plasmid 
vector. Finger-
prints found in 
both sub-libraries 
are underlined. 
Each HMR finger-
print is an elec-
trophoretogram 
consisting of three 
gel lanes with 
separated DNA 
fragments ob-
tained after paral-
lel treatment of the 
PCR product (an 
amplified nanoan-
tibody sequence) 
with one of three 
restrictases, HinfI 
(H), MspI (M) or 
RsaI (R), and the 
forth lane with 
marker DNA (the 
sizes of the marker 
DNA fragments are 
shown at the bot-
tom of the figure).
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corresponding nanoantibodies in the host bacteria’s 
periplasm. The periplasmic extracts were then tested 
with ELISA for the presence of a nanoantibody that 
binds to a given antigen. The same preparations of the 
Rabies virus and anthrax lethal factor that were used 
for camel immunisation were used as antigens for the 
selection procedures and ELISA. The increase in the 
absorbance value at 405 nm in the plate wells reflect-
ed two processes: the level of expression/availability 
of the nanoantibody and the strength of its interaction 
with the immobilized antigen. Information pertaining 
to the selection of the final nanoantibody clones bind-
ing to a given antigen is presented in Figs. 2 and 3 and 
in Tables 1 and 2.
It is necessary to exert caution when interpreting 
the data. It is possible that some clones differing in 
nucleotide and amino acid sequences will have simi-
lar fingerprints, especially when sampled clones are 
compared to random clones from the original library. 
Sequencing can, naturally, provide more information. 
Our experience, however, shows that in most cases 
of clone identification the HMR analysis can replace 
Fig. 2. HMR 
fingerprints of the 
selected nanoan-
tibody clones 
that bind in ELISA 
to immobilised 
recombinant 
anthrax lethal fac-
tor. These clones 
are designated 
as “alf” with a 
number.
Table 1. Relative representation of fingerprint variants of selected nanoantibody clones recognizing the anthrax lethal 
factor (alf), at various selection stages.
alf clone 
number
1st stage, 
normal helper 
phage
1st stage, 
mutant helper 
phage
2nd stage, 
normal helper 
phage
2nd stage, 
mutant helper 
phage
3rd stage, 
normal helper 
phage
3rd stage, 
mutant helper 
phage
ELISA 
signal
1 3/28 0/27 3/30 0/43 3/42 5/43 ++
2 0/28 1/27 3/30 0/43 0/42 0/43 +++
3 1/28 0/27 0/30 0/43 3/42 3/43 ++
4 2/28 0/27 0/30 0/43 1/42 0/43 +
5 2/28 0/27 0/30 1/43 0/42 1/43 +
6 3/28 0/27 12/30 0/43 12/42 13/43 ++
7 0/28 0/27 0/30 0/43 0/42 1/43 +++
8 0/28 0/27 0/30 0/43 0/42 2/43 ++
9 1/28 0/27 0/30 1/43 1/42 1/43 ++
10 1/28 0/27 3/30 0/43 2/42 1/43 +++
11 0/28 0/27 0/30 0/43 0/42 1/43 ++
12 0/28 0/27 0/30 0/43 1/42 1/43 ++
13 1/28 0/27 2/30 0/43 6/42 2/43 ++
14 0/28 0/27 2/30 1/43 2/42 2/43 +++
Note: Here and in Table 2 the clones used for the production and ELISA of corresponding nanoantibodies are in bold font. 
The number of “+” signs correlated with the relative increase in the ELISA signal (absorbance).RESEARCH ARTICLES
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sequencing; therefore, it makes it a more economical 
technique.
HMR analysis of nanoantibodies recognizing anthrax 
lethal factor
Figure 2 shows the HMR fingerprints of 14 variants of 
the selected nanoantibody samples (alf) that recognize 
the anthrax lethal factor. There were only 5 out of the 
14 for which we could find similar fingerprints among 
the 85 variants from the original library - the corre-
sponding pairs being alf3—68N, alf6—59, alf8—62N, 
alf9—58, and alf10—64. Even though these 5 pairs are 
similar, that doesn’t necessarily make them identical. 
Thus, the alf8 clone fingerprint variant was not found 
among 28–30 analyzed clones after the first and sec- analyzed clones after the first and sec-  clones after the first and sec-
ond selection stages; it appeared only after the third 
selection stage and only when the mutant helper phage 
was used. On the other hand, the alf6 clone fingerprint 
variant may well correspond to one of the most rep-
resentative variants in the original library, since this 
variant remains one of the most represented after each 
selection stage.
We would like to note here a rather unexpected 
phenomenon related to the modified selection method 
using the hp∆MBpIII helper phage. When nanoanti-
bodies to each of the two antigens were being selected 
(Tables 1 and 2), enrichment of specific clone variants 
was observed during the first two selection stages, 
which were different from the 85 variants presented 
in Fig. 1 and those enriched using the traditional helper 
phage. Unfortunately, the nanoantibodies coded for by 
those clones did not bind to the corresponding antigens 
Table 2. Relative representation of fingerprint variants of selected nanoantibody clones recognizing Rabies virus prepa-
ration (aRv), at various selection stages.
aRv clone number 2nd stage, normal 
helper phage
2nd stage, mutant 
helper phage
3rd stage, normal 
helper phage
3rd stage, mutant 
helper phage ELISA signal
1 0/67 3/45 1/30 2/58 +
2 7/67 1/45 5/30 2/58 +
3 13/67 0/45 8/30 11/58 ++
4 0/67 0/45 2/30 0/58 +++
5 4/67 1/45 1/30 0/58 +
6 0/67 0/45 1/30 0/58 +
7 0/67 0/45 0/30 1/58 +++
8 2/67 0/45 0/30 0/58 +
9 1/67 1/45 0/30 0/58 +
10 1/67 0/45 0/30 0/58 +
11 1/67 0/45 0/30 0/58 ++
12 2/67 0/45 0/30 0/58 +++
13 4/67 0/45 0/30 2/58 ++
14 0/67 2/45 0/30 0/58 ++
15 1/67 0/45 0/30 0/58 +
16 1/67 0/45 0/30 0/58 +++
17 3/67 1/45 2/30 1/58 ++
Fig. 3. HMR 
fingerprints of 
the selected 
nanoantibody 
clones that bind 
in ELISA to im-
mobilised Rabies 
virus. These 
clones are des-
ignated as “aRv” 
with a number.92 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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in ELISA. Those clones were effectively sorted out at 
later selection stages. We believe that those temporar-
ily selected clones bind to the blocking agent and are 
then sorted out when the blocking agent is replaced. 
Apparently, some nanoantibodies, more easily availa-
ble on the surface of the mutant phage, can either bind 
to a component of Skim milk (at the first stage) or to 
BSA (at the second stage). At the third selection stage, 
when Skim milk was used again, a sharp clearing of 
the nonspecific background occurred. The nonspecific 
clones enriched at the first and second stages were dis-
appearing, and the fingerprints of the sought specific 
clones appeared, many of them identical to the clones 
selected in the parallel traditional procedure (Table 1, 
clones alf1, alf3, alf6, alf9, alf10, alf12, alf13, and alf14). 
Interestingly, similar to our previous work [11], some 
nanoantibody variants could only be selected with the 
modified selection procedure (Table 1, clones alf5, alf7, 
alf8, and alf11). There were also variants that could 
only be selected with the standard procedure (clone 
alf2 at the second stage and clone alf4). Interestingly, 
the nanoantibody clones that produce the strongest 
ELISA absorbance signal were not necessarily the most 
represented among the selected clones and could even 
disappear after the subsequent selection stages (alf2). 
The most enrichment was observed for the clones that 
produced medium intensity ELISA absorbance signal.
HMR analysis of nanoantibodies recognizing Rabies 
virus preparation
The findings described above were reaffirmed during 
the selection of nanoantibodies (aRv) recognizing the 
Rabies virus preparation (Fig. 3, Table 2).
In that case, a similar fingerprint could only be 
found for 5 out of the 17 finally selected clones among 
the 85 variants in the original library: aRv2—32, 
aRv3—12N, aRv5—75N, aRv13—76N, and aRv17—
46N. The aRv3 clone fingerprint may well be one of 
the most represented variants in the original library, 
since this variant remains the most represented af-
ter (repeating) each selection stage with the stand-
ard helper phage. When the mutant helper phage 
was used for the selection of this fingerprint vari -
ant, it was clear that, as in the case of selection of 
nanoantibodies recognizing the anthrax lethal fac-
tor, the nonspecific background cleared after the 
third stage with blocking agent replacement. In this 
case, the parallel use of the traditional and the modi-
fied selection methods also ensured a wider variety 
of selected nanoantibody clones. Thus, in using only 
the traditional procedure, the fingerprint variants 
corresponding to the following clones were selected: 
aRv4, aRv6, aRv8, aRv10, aRv11, aRv12, aRv15, and 
aRv16. But while using the modified procedure alone, 
variants aRv7, aRv13, and aRv14 were selected. The 
aRv13 variant was also selected after the second 
stage of the traditional procedure, but it disappeared 
after the third stage.
It is interesting that in this case as well, the nanoan-
tibody clones producing the strongest ELISA absor- ELISA absor-
bance signal were not the most represented among the 
selected clones. Only a small number of the aRv4, aRv7, 
aRv12, and aRv16 clones were selected, and by using 
only one of two selection methods. Some of these clones 
(aRv12 and aRv16) can be easily lost at the third selec-
tion stage.
CONCLUSION
Parallel selection using the traditional helper phage 
and a modified helper phage with N-terminal dele-
tion in the gIII surface protein is recommended for 
improving the efficiency of phage display selection of 
nanoantibodies with a required specificity. The modi-
fied procedure should take into account the higher 
nonspecific background, which is apparently due to 
the selection of phage particles containing nanoan-
tibodies that bind to the blocking agents or to other 
nonspecific components. We cannot exclude a possibil-  components. We cannot exclude a possibil- We cannot exclude a possibil-
ity of specific binding to the antigen of a special kind 
of nanoantibody, which is happening only when it is 
exposed on the phage’s surface and which disappears 
in the case of stand-alone nanoantibody. The sequen-
tial use of different blocking agents in combination 
with the proposed mutant helper phage reduces the 
nonspecific background significantly after three selec-  background significantly after three selec-
tion stages. One should be aware that some important 
nanoantibodies might be lost during additional ampli-
fication/selection stages. We recommend analyzing 
selected clones after the second and third selection 
stages when performing the traditional procedure, 
and after the third stage when performing the modi-
fied procedure. Good results are also obtained when 
the modified method is used after the initial stage of 
the traditional selection procedure. 
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